Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population

Hum Vaccin Immunother. 2017 Aug 3;13(8):1873-1878. doi: 10.1080/21645515.2017.1316913. Epub 2017 Apr 27.

Abstract

Objective This study was conducted to assess the cost-effectiveness of hepatitis E vaccination of elderly population in the sporadic regions in China. Methods We used a decision tree-Markov model to evaluate the cost-effectiveness of 3 kinds of hepatitis E virus vaccination strategies from societal perspectives. Parameter estimates were obtained from published researches and experts' opinion. The time horizon was 16 years, and the discounted rate was 3% annually. Costs are expressed in 2016 US dollars. Results The universal vaccination strategy had an incremental cost-effectiveness ratio (ICER) of US$ 8475.90 per QALY gained versus no vaccination. The implementation of screening and vaccination strategy would have an ICER of US$ 4044.28, compared with no vaccination. The vaccination was cost-effective (ICER< 3 times China's per capital gross domestic product/quality-adjusted life years). The QALY of asymptomatic infection, vaccine coverage and vaccine protection are the important parameters impacting the ICER in one-way sensitivity analysis and screening and vaccination being the dominant strategy in probabilistic sensitivity analysis. Conclusion This analysis indicates that screening and vaccination is the most cost-effective hepatitis E intervention strategy of elderly population in sporadic region in China.

Keywords: Cost-effectiveness analysis; Economic evaluation; Elderly population; Hepatitis E vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • China / epidemiology
  • Cost-Benefit Analysis
  • Female
  • Hepatitis E / epidemiology
  • Hepatitis E / prevention & control*
  • Hepatitis E virus / immunology*
  • Humans
  • Immunization Programs / economics*
  • Immunization Programs / statistics & numerical data
  • Male
  • Markov Chains
  • Vaccination / economics*
  • Viral Hepatitis Vaccines / economics*

Substances

  • Viral Hepatitis Vaccines